Video Series

Cytokine release syndrome can limit aggressive RRMM treatment strategies.

Panelists discuss relapsed/refractory multiple myeloma treatment regimen strategies.

The panel measures the significance of an RSV vaccine in relation to other vaccines in circulation.

Traditionally thought of as a pediatric disease, RSV also affects older patient populations.

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

Soyini Hawkins, MD, MPH, FACOG, drives a conversation regarding the impact of race in diagnosing endometriosis.

Early detection of uterine fibroids and endometriosis has been powered by the Affordable Care Act, ultimately improving prognosis for patient outcomes.

Key opinion leaders dive into the use of bispecific treatment options for RRMM.

Various treatment options for patients with relapsed/refractory MM are discussed.

Adam C. Welch, PharmD, MBA, FAPhA, leads a panel discussion surrounding complications related to RSV infection.

A panel of medical experts discuss the prevalence of RSV in adults.

Dr Butrus leads a discussion on the ideal patient population for treating atopic dermatitis with ruxolitinib.

The panelists highlight the treatment nature of ruxolitinib, a JAK inhibitor used to treat atopic dermatitis.

Medical experts provide insights surrounding efforts to ensure equitable health for women across underserved patient populations.

Derek van Amerongen, MD, MS, leads a panel discussion surrounding disparities currently facing women in health care.

Dr Matous leads a conversation regarding CAR T-cell therapy for treating multiple myeloma.

The panel provides an overview of drug treatment options for patients with RRMM.

Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life.

Medical experts navigate the selection process for optimal atopic dermatitis treatment strategies from provider and payer perspectives.

In her closing thoughts, Dr Michos highlights social determinants of health impacting the treatment landscape for patients with cardiovascular disease.

Inclusivity in clinical trials to achieve equitable care.

Derek van Amerongen, MD, MS, drives a panel discussion surrounding disparities currently faced by women in health care.

A panel of multiple myeloma experts discuss costs associated with relapsed/refractory disease.

Treatment considerations for relapsing multiple myeloma is discussed by key opinion leaders.

Brian Keegan, MD, PhD, and Michael Cameron, MD, FAAD, describe treatment options for patients with atopic dermatitis.

Dr Casey Butrus drives a discussion highlighting typical patient presentations of AD.

In their final thoughts, the panelists explore the future of GA treatment strategies.

Dr Khanani discusses how to monitor patients with geographic atrophy for adverse events.

Key opinion leaders discuss clinical and cost considerations for treating patients diagnosed with geographic atrophy.